- Quotient (NASDAQ:QTNT) received Conformité Européenne (CE) Mark for its MosaiQ Extended Immunohematology (IH) Microarray.
- The status allows the company to sell the microarray for use with its MosaiQ instrument across the EU.
- The company said its MosaiQ platform offers an all-in-one, fully automated, solution in blood-testing laboratory and other settings. The IH microarray increases the range of tests that can be run on the platform.
- The IH microarray offers antibody screening, antigen typing, including ABO forward and reverse grouping.
Recommended For You
More Trending News
See More »